Français
Search this site:
Symbol
Last
Change
IPN.PA
27.54 €
(+1.06 % )
powered by Euronext©
The Group
Profile & Key figures
Message from the Chairman
Group history
Strategy
R & D
R & D Homepage
Oncology
Endocrinology
Neurology
Primary care
Medicines
Governance
Board of directors
Executive committee
Board committees
Business Development & Alliance Management
Ipsen worldwide
Targeted diseases
Oncology
Endocrinology
Neurology
Hematology
Primary care
Commitments
Vision, mission and values
Environment, health and safety
Ethics and compliance
Support to Patient Organizations
Solidarity
Fondation IPSEN
La Fondation Ipsen at a glance
Colloques, prizes, publications
Neurosciences
Alzheimer’s disease
Endocrinology
Cancer science
Longevity
Vascular
Partnerships
Salk Institute - Nature
Cell Press - Massachusetts General Hospital
Nature Publishing Group
Home
> Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme
Press release
18 June 2010
- Paris (France)
Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme
Download
Go to
Press room
Investor relations
Careers
2009 Ipsen Annual Report
Read the interactive document
